Skip to content

A real-world observational study of 13N-ammonia PET myocardial perfusion imaging in the precise diagnosis of ischaemic heart disease

A real-world observational study of 13N-ammonia PET myocardial perfusion imaging in the precise diagnosis of ischaemic heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125365
Enrollment
Unknown
Registered
2026-05-26
Start date
2026-05-31
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemic heart disease

Interventions

13N-Ammonia PET:None

Sponsors

The First Affiliated Hospital of the Air Force Medical University of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with suspected or confirmed ischaemic heart disease who require myocardial perfusion imaging and/or coronary flow reserve (CFR) assessment; 2. Patients who voluntarily agree to undergo 13N-ammonia PET/CT or PET/MR scanning, have signed an informed consent form, demonstrate good compliance, and are able to cooperate fully with the examination and follow-up.

Exclusion criteria

Exclusion criteria: 1. Unstable angina, acute coronary syndrome, or within 2 to 4 days following an acute myocardial infarction; 2. Sick sinus syndrome or symptomatic bradycardia, without an active pacemaker; 3. Second- or third-degree atrioventricular block without a functional pacemaker; 4. Systolic blood pressure below 90 mmHg. The risk associated with severe hypotension is higher in patients with autonomic dysfunction, hypovolaemia, stenosis of the left main coronary artery, valvular heart disease with stenosis, pericarditis, pericardial effusion, or carotid artery stenosis associated with cerebrovascular insufficiency; 5. Uncontrolled hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg); 6. Patients with persistent wheezing and bronchospastic lung disease, or those with a history of significant reactive airway disease, should not undergo an adenosine stress test; 7. Known hypersensitivity to adenosine; 8. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Baseline MBF in each myocardial segment;Maximum blood flow (MBF) in each segment of the myocardium;CFR values for each myocardial segment;

Secondary

MeasureTime frame
Check operation time;

Countries

China

Contacts

Public ContactXiang Li

The First Affiliated Hospital of the Air Force Medical University of the People's Liberation Army of China

2326604944@qq.com+86 29 8477 1048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026